WO2010019450A3 - Synergizing active compounds for treating inflammation and other conditions - Google Patents

Synergizing active compounds for treating inflammation and other conditions Download PDF

Info

Publication number
WO2010019450A3
WO2010019450A3 PCT/US2009/053040 US2009053040W WO2010019450A3 WO 2010019450 A3 WO2010019450 A3 WO 2010019450A3 US 2009053040 W US2009053040 W US 2009053040W WO 2010019450 A3 WO2010019450 A3 WO 2010019450A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
synergizing
conditions
active compounds
inflammation
Prior art date
Application number
PCT/US2009/053040
Other languages
French (fr)
Other versions
WO2010019450A2 (en
Inventor
Nyles Bauer
Original Assignee
Nyles Bauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyles Bauer filed Critical Nyles Bauer
Publication of WO2010019450A2 publication Critical patent/WO2010019450A2/en
Publication of WO2010019450A3 publication Critical patent/WO2010019450A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Compositions and methods are provided having unexpected anti-inflammatory and other properties based on unprecedented synergistic effects of administering two or more of (i) an opiate antagonist, partial antagonist, or reverse agonist, (ii) a cAMP-phosphodiesterase (PDE) inhibitor, (iii) an adenylate cyclase activator, and (iv) a nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidase inhibitor. Invention embodiments are useful for treating or reducing one or more of tissue inflammation, inflammation-associated cellular proliferation, oxidative stress or neuronal death or dysfunction, or for treating or preventing gray hair or restoring hair color.
PCT/US2009/053040 2008-08-09 2009-08-06 Synergizing active compounds for treating inflammation and other conditions WO2010019450A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8769508P 2008-08-09 2008-08-09
US61/087,695 2008-08-09

Publications (2)

Publication Number Publication Date
WO2010019450A2 WO2010019450A2 (en) 2010-02-18
WO2010019450A3 true WO2010019450A3 (en) 2010-05-06

Family

ID=41669585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053040 WO2010019450A2 (en) 2008-08-09 2009-08-06 Synergizing active compounds for treating inflammation and other conditions

Country Status (1)

Country Link
WO (1) WO2010019450A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102078614B (en) * 2010-12-27 2012-07-25 温州医学院眼视光研究院 Method for inhibiting shortsightedness and application of adenylate cyclase inhibitor as medicament for inhibiting shortsightedness
FR2973704B1 (en) * 2011-04-11 2014-09-05 Fabre Pierre Dermo Cosmetique PEPTIDYL-ARGININE 1 AND / OR 3 EPIDERM ACTIVATOR COMPOUNDS IN EPIDERM AND USES THEREOF
US20120307919A1 (en) * 2011-06-06 2012-12-06 Jukka Tapio Ranta Control of Cell Search Procedure
EP2753332B1 (en) * 2011-09-09 2017-02-15 SK Chemicals Co., Ltd. Mridenafil for reducing skin wrinkles
US10702544B2 (en) 2016-01-12 2020-07-07 National University Corporation Tokyo Medical And Dental University Composition for ameliorating loss of hair and graying of hair, and use thereof
EP3595623B1 (en) 2017-03-14 2024-05-01 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
US11033549B2 (en) 2017-03-14 2021-06-15 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
EP3651861A1 (en) * 2017-07-14 2020-05-20 Life Science Investments Ltd. Cosmetic composition comprisingcoleus forskohlii

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017368A (en) * 1987-06-01 1991-05-21 Keikichi Sugiyama Composition for application to hair or scalp
US6333354B1 (en) * 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US6333057B1 (en) * 1995-07-03 2001-12-25 Wilson T. Crandall Composition and method for topical treatment of androgenic alopecia
US20050009847A1 (en) * 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20060020020A1 (en) * 1999-01-13 2006-01-26 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017368A (en) * 1987-06-01 1991-05-21 Keikichi Sugiyama Composition for application to hair or scalp
US6333057B1 (en) * 1995-07-03 2001-12-25 Wilson T. Crandall Composition and method for topical treatment of androgenic alopecia
US6333354B1 (en) * 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US20060020020A1 (en) * 1999-01-13 2006-01-26 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20050009847A1 (en) * 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAMOTO E ET AL.: "Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.", STROKE., vol. 39, no. 11, November 2008 (2008-11-01), pages 3049 - 3056 *

Also Published As

Publication number Publication date
WO2010019450A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010019450A3 (en) Synergizing active compounds for treating inflammation and other conditions
WO2010035219A3 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors
WO2005110477A3 (en) Combination therapies for cancer and proliferative angiopathies
CA2566716C (en) Prolongation of survival of an allograft by inhibiting complement activity
MX2010006154A (en) Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors.
WO2006066109A3 (en) Hydroxysteroid dehydrogenase inhibitors
TW200942536A (en) PIM kinase inhibitors and methods of their use
WO2005112646A3 (en) Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds
MX2009004700A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors.
WO2006011631A3 (en) Thiazole derivatives having vap-1 inhibitory activity
BRPI0718803B8 (en) compound to inhibit mitotic progression, pharmaceutical composition and in vitro method to inhibit aurora kinase activity in a cell
WO2007146124A3 (en) Deuterated tadalafil derivatives
HK1107084A1 (en) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoÄ2,3-dÜpyrimidine derivatives and related compoundsfor the treatment of cancer
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
WO2007062167A3 (en) Method of modulating stress-activated protein kinase system
WO2008003028A3 (en) Pharmaceutical compositions comprising droxidopa
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
TW200510380A (en) Mitotic kinesin inhibitors
EP2067467A3 (en) Compositions and methods for treating keratinous substrates
MX2010004312A (en) Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity.
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
UA97256C2 (en) Substituted pyrazole and triazole compounds as ksp (kinesin spindle protein) inhibitors
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
MX2009001966A (en) Method of reducing neuronal cell damage.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09807098

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.07.2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09807098

Country of ref document: EP

Kind code of ref document: A2